open access

Vol 71, No 4 (2021)
Review paper
Published online: 2021-08-18
Get Citation

Personalised medical management of patients with melanoma (part 2)

Justyna Gil, Izabela Łaczmańska, Maria M. Sąsiadek, Marcin Ziętek
DOI: 10.5603/NJO.2021.0045
·
Nowotwory. Journal of Oncology 2021;71(4):251-254.

open access

Vol 71, No 4 (2021)
Genetics and oncology
Published online: 2021-08-18

Abstract

In recent years, a dynamic increase has been observed in occurrence of melanomas, especially in young and middle-aged patients. This is the reason why curing these patients has become a priority also in the economic context. Melanomas belong to a group of neoplasms of very high genetic heterogeneity. The most common genetic alterations concern two signalling pathways: mitogen activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathway. Identification of the characteristic molecular changes in the neoplastic tissue allows optimisation and individualisation of the therapy. Thus, it contributes to an increase in successful cancer treatment, reduction of treatment side effects and to improvement of the patients’ quality of life. Currently, the standard management of skin melanoma patients involves – along with surgical treatment and classical chemo/radiotherapy which is now less frequently used – also introduction of targeted therapy focused on molecular changes within the tumour tissue as well as immunotherapy which relies on activating the immune system.

Abstract

In recent years, a dynamic increase has been observed in occurrence of melanomas, especially in young and middle-aged patients. This is the reason why curing these patients has become a priority also in the economic context. Melanomas belong to a group of neoplasms of very high genetic heterogeneity. The most common genetic alterations concern two signalling pathways: mitogen activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathway. Identification of the characteristic molecular changes in the neoplastic tissue allows optimisation and individualisation of the therapy. Thus, it contributes to an increase in successful cancer treatment, reduction of treatment side effects and to improvement of the patients’ quality of life. Currently, the standard management of skin melanoma patients involves – along with surgical treatment and classical chemo/radiotherapy which is now less frequently used – also introduction of targeted therapy focused on molecular changes within the tumour tissue as well as immunotherapy which relies on activating the immune system.

Get Citation

Keywords

melanoma; BRAF; NRAS; targeted therapy

About this article
Title

Personalised medical management of patients with melanoma (part 2)

Journal

Nowotwory. Journal of Oncology

Issue

Vol 71, No 4 (2021)

Article type

Review paper

Pages

251-254

Published online

2021-08-18

DOI

10.5603/NJO.2021.0045

Bibliographic record

Nowotwory. Journal of Oncology 2021;71(4):251-254.

Keywords

melanoma
BRAF
NRAS
targeted therapy

Authors

Justyna Gil
Izabela Łaczmańska
Maria M. Sąsiadek
Marcin Ziętek

References (22)
  1. Rutkowski P, Wysocki PJ, Nasierowska-Guttmejer A, et al. Cutaneous melanomas. Oncol Clin Pract. 2020; 16(4): 163–182.
  2. Mikula H, Stapleton S, Kohler RH, et al. Design and Development of Fluorescent Vemurafenib Analogs for Imaging. Theranostics. 2017; 7(5): 1257–1265.
  3. Koseła H, Świtaj T, Rutkowski P. Zastosowanie inhibitorów BRAF i MEK w terapii zaawansowanego czerniaka. Onkol Prak Klin. 2011; 7(5): 246–253.
  4. Giunta EF, De Falco V, Napolitano S, et al. Optimal treatment strategy for metastatic melanoma patients harboring mutations. Ther Adv Med Oncol. 2020; 12: 1758835920925219.
  5. Robert C, Grob JJ, Stroyakovskiy D, et al. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. N Engl J Med. 2019; 381(7): 626–636.
  6. Lewis KD, Larkin J, Ribas A, et al. Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM. Br J Cancer. 2019; 121(7): 522–528.
  7. Spagnolo F, Ghiorzo P, Orgiano L, et al. BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies. Onco Targets Ther. 2015; 8: 157–168.
  8. Kozar I, Margue C, Rothengatter S, et al. Many ways to resistance: How melanoma cells evade targeted therapies. Biochim Biophys Acta Rev Cancer. 2019; 1871(2): 313–322.
  9. Smalley KSM, McArthur GA. The current state of targeted therapy in melanoma: this time it's personal. Semin Oncol. 2012; 39(2): 204–214.
  10. Ascierto P, Schadendorf D, Berking C, et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol. 2013; 14(3): 249–256.
  11. Pham DD, Guhan S, Tsao H. KIT and Melanoma: Biological Insights and Clinical Implications. Yonsei Med J. 2020; 61(7): 562–571.
  12. Ricci SB, Cerchiari U. Spontaneous regression of malignant tumors: Importance of the immune system and other factors (Review). Oncol Lett. 2010; 1(6): 941–945.
  13. Isakov N. Cancer immunotherapy by targeting immune checkpoint receptors. World J Immunol. 2018; 8(1): 1–11.
  14. Chae YK, Arya A, Iams W, et al. Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). J Immunother Cancer. 2018; 6(1): 39.
  15. Callahan MK, Postow MA, Wolchok JD. Immunomodulatory therapy for melanoma: ipilimumab and beyond. Clin Dermatol. 2013; 31(2): 191–199.
  16. Sahni S, Valecha G, Sahni A. Role of Anti-PD-1 Antibodies in Advanced Melanoma: The Era of Immunotherapy. Cureus. 2018; 10(12): e3700.
  17. Munhoz RR, Postow MA. Clinical Development of PD-1 in Advanced Melanoma. Cancer J. 2018; 24(1): 7–14.
  18. Johnson DB, Lovly CM, Flavin M, et al. Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies. Cancer Immunol Res. 2015; 3(3): 288–295.
  19. Rose AAN, Armstrong SM, Hogg D, et al. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy. J Immunother Cancer. 2021; 9(1).
  20. Coit DG, Thompson JA, Albertini MR, et al. Cutaneous melanoma, version 2. JNCCN. 2019; 17: 367–402.
  21. Simeone E, Ascierto PA. Anti-PD-1 and PD-L1 antibodies in metastatic melanoma. Melanoma Manag. 2017; 4(4): 175–178.
  22. Carlino MS, Menzies AM, Atkinson V, et al. Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B. Clin Cancer Res. 2020; 26(19): 5086–5091.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media sp. z o.o. VM Group sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl